REVENUES (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

The following table summarizes our Total revenues:


	Three Months Ended March 31, 2023								Three Months Ended March 31, 2022
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
HIV
Biktarvy	$	2,161	$	304	$	212	$	2,677	$	1,706	$	261	$	184	$	2,151
Complera/Eviplera	14		22		3		39		17		24		4		44
Descovy	395		25		29		449		311		32		31		374
Genvoya	417		55		29		501		457		77		48		582
Odefsey	230		76		11		317		232		96		11		339
Stribild	20		6		2		28		22		8		3		32
Truvada	23		3		5		32		28		4		6		38
Revenue share - Symtuza(1)	98		36		4		138		86		44		3		132
Other HIV(2)	4		1		3		9		5		4		5		14
Total HIV	3,364		528		298		4,190		2,862		550		295		3,707
Oncology
Cell Therapy
Tecartus	59		27		3		89		47		15		1		63
Yescarta	210		121		28		359		125		77		9		211
Total Cell Therapy	269		148		31		448		172		92		10		274

Trodelvy	162		54		6		222		119		25		2		146
Total Oncology	431		202		37		670		292		117		11		420
Liver Disease
Chronic hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)	3		7		5		15		13		4		18		35
Sofosbuvir/Velpatasvir(4)	204		90		90		385		162		83		85		330
Other HCV(5)	24		18		4		45		24		8		2		34
Total HCV	232		114		99		445		199		95		105		399

Chronic hepatitis B virus (“HBV”) / hepatitis delta virus (“HDV”)
Vemlidy	87		9		103		199		80		9		111		200
Viread	(1)		6		14		19		—		6		17		23
Other HBV/HDV(6)	—		11		—		11		—		13		—		13
Total HBV/HDV	86		26		117		230		80		28		128		235
Total Liver Disease	318		140		217		675		279		123		233		635

Veklury	252		111		209		573		801		304		430		1,535
Other
AmBisome	6		60		49		116		25		66		53		144
Letairis	32		—		—		32		43		—		—		43
Other(7)	30		12		9		51		26		15		9		50
Total Other	69		72		58		199		94		81		62		236
Total product sales	4,434		1,053		819		6,306		4,329		1,174		1,031		6,534
Royalty, contract and other revenues	18		26		2		46		27		27		3		56
Total revenues	$	4,452	$	1,079	$	821	$	6,352	$	4,355	$	1,202	$	1,033	$	6,590

_______________________________

(1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2) Includes Atripla, Emtriva, Sunlenca and Tybost.

(3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5) Includes Vosevi and Sovaldi.

(6) Includes Hepcludex and Hepsera.

(7) Includes Cayston, Jyseleca, Ranexa and Zydelig.

Summary of Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:


	Three Months Ended
	March 31,
(as a percentage of total revenues)	2023		2022
AmerisourceBergen Corporation	18	%	19	%
Cardinal Health, Inc.	26	%	23	%
McKesson Corporation	20	%	20	%

Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior periods:


	Three Months Ended
	March 31,
(in millions)	2023		2022
Revenue share with Janssen and royalties for licenses of intellectual property	$	192	$	184
Changes in estimates	$	160	$	230

Summary of Contract Balances

The following table summarizes our contract balances:


(in millions)	March 31, 2023		December 31, 2022
Contract assets(1)	$	164	$	171
Contract liabilities(2)	$	93	$	102

________________________________

(1) Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.

(2) Generally results from receipt of advance payment before our performance under the contract.